Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Product revenue analysis (bottom-up approach)
    • 2.2.1.2 Revenue share analysis of Regeneron Pharmaceuticals, Inc.
    • 2.2.1.3 MnM repository analysis
    • 2.2.1.4 Primary interviews
  • 2.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 OPHTHALMOLOGY DRUGS MARKET OVERVIEW
• 4.2 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE
• 4.3 OPHTHALMOLOGY DRUGS MARKET SHARE, BY END USER, 2024
• 4.4 OPHTHALMOLOGY DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Aging population and growing prevalence of vision disorders
    • 5.2.1.2 Strong drug pipeline and growing innovation efforts
    • 5.2.1.3 Increasing investments and strategic collaborations
    • 5.2.1.4 Improved reimbursement policies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Off-label drug use for various indications
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Shifting focus on new drug modalities
    • 5.2.3.2 Expansion into emerging markets
    • 5.2.3.3 High unmet needs
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Hybridoma technology
    • 5.3.1.2 Recombinant DNA technology
    • 5.3.1.3 Antibody engineering
    • 5.3.1.4 Gene therapy
    • 5.3.1.5 Nanoformulations
  • 5.3.2 ADJACENT TECHNOLOGIES
    • 5.3.2.1 Optogenetic technology
    • 5.3.2.2 Drug-release technologies
    • 5.3.2.3 Ocular implant technologies
  • 5.3.3 COMPLEMENTARY TECHNOLOGIES
    • 5.3.3.1 3D printing and bioprinting
    • 5.3.3.2 Ocular imaging technologies
• 5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024
  • 5.5.2 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
  • 5.5.3 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 OPHTHALMOLOGY DRUGS MARKET: ROLE OF RAW MATERIAL SUPPLIERS
  • 5.7.2 OPHTHALMOLOGY DRUGS MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES
  • 5.7.3 OPHTHALMOLOGY DRUGS MARKET: ROLE OF END USERS
  • 5.7.4 OPHTHALMOLOGY DRUGS MARKET: ROLE OF REGULATORY AUTHORITIES
• 5.8 PATENT ANALYSIS
• 5.9 REGULATORY ANALYSIS
  • 5.9.1 REGULATORY LANDSCAPE
    • 5.9.1.1 US
    • 5.9.1.2 Europe
    • 5.9.1.3 Emerging markets
  • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.10 PORTER'S FIVE FORCES ANALYSIS
  • 5.10.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10.2 BARGAINING POWER OF SUPPLIERS
  • 5.10.3 BARGAINING POWER OF BUYERS
  • 5.10.4 THREAT OF SUBSTITUTES
  • 5.10.5 THREAT OF NEW ENTRANTS
• 5.11 KEY CONFERENCES & EVENTS, 2025-2026
• 5.12 REIMBURSEMENT SCENARIO
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS
• 5.14 INVESTMENT & FUNDING SCENARIO
• 5.15 PIPELINE ANALYSIS
• 5.16 IMPACT OF ARTIFICIAL INTELLIGENCE ON OPHTHALMOLOGY DRUGS MARKET
  • 5.16.1 CHALLENGES IN DRUG DISCOVERY
  • 5.16.2 IMPACT OF AI ON DISCOVERY OF OPHTHALMOLOGY DRUGS
• 5.17 IMPACT OF 2025 US TARIFFS ON OPHTHALMOLOGY DRUGS MARKET
  • 5.17.1 KEY TARIFF RATES
  • 5.17.2 PRICE IMPACT ANALYSIS
  • 5.17.3 KEY IMPACT ON VARIOUS REGIONS
    • 5.17.3.1 US
    • 5.17.3.2 Europe
    • 5.17.3.3 APAC
  • 5.17.4 MANUFACTURING INDUSTRY IMPACT
    • 5.17.4.1 Ophthalmology drug manufacturers

6 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE

• 6.1 INTRODUCTION
• 6.2 AFLIBERCEPT
  • 6.2.1 HIGH EFFICIENCY OF AFLIBERCEPT IN TREATING RETINAL DISEASES TO DRIVE MARKET GROWTH
• 6.3 FARICIMAB
  • 6.3.1 GROWING ADOPTION AND POSITIVE OUTCOMES OF STUDIES TO SUPPORT MARKET GROWTH
• 6.4 RANIBIZUMAB
  • 6.4.1 CLINICAL EFFICACY OF RANIBIZUMAB TO DRIVE ADOPTION
• 6.5 OTHER MOLECULES

7 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY

• 7.1 INTRODUCTION
• 7.2 MONOCLONAL ANTIBODIES & FUSION PROTEINS
  • 7.2.1 GROWING FOCUS ON DEVELOPING NEW MABS TO DRIVE MARKET
• 7.3 SMALL MOLECULES
  • 7.3.1 INCREASING INVESTMENTS AND RESEARCH TO DRIVE MARKET
• 7.4 OTHER MODALITIES

8 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION

• 8.1 INTRODUCTION
• 8.2 AGE-RELATED MACULAR DEGENERATION
  • 8.2.1 WET AGE-RELATED MACULAR DEGENERATION
    • 8.2.1.1 Increasing demand for effective therapies to drive market
  • 8.2.2 DRY AGE-RELATED MACULAR DEGENERATION
    • 8.2.2.1 Large market opportunity for innovation to drive growth
• 8.3 DIABETIC RETINOPATHY (DR)
  • 8.3.1 FEWER APPROVED DRUGS TO PRESENT MARKET OPPORTUNITIES
• 8.4 DIABETIC MACULAR EDEMA (DME)
  • 8.4.1 GROWING ADOPTION OF APPROVED ANTI-VEGF DRUGS FOR DME TO DRIVE MARKET
• 8.5 OTHER INDICATIONS

9 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

• 9.1 INTRODUCTION
• 9.2 INTRAVITREAL
  • 9.2.1 HIGH EFFICACY OF INTRAVITREAL INJECTIONS IN TREATMENT OF MAJOR RETINAL DISEASES TO DRIVE MARKET
• 9.3 TOPICAL
  • 9.3.1 EASE OF USE TO DRIVE DEMAND FOR TOPICAL DRUGS
• 9.4 OTHER ROUTES OF ADMINISTRATION

10 OPHTHALMOLOGY DRUGS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO ENCOURAGE GROWTH
• 10.3 LONG-TERM CARE FACILITIES
  • 10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET
• 10.4 SPECIALTY CENTERS
  • 10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH

11 OPHTHALMOLOGY DRUGS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Rising investments in healthcare research and development to support growth
  • 11.2.3 CANADA
    • 11.2.3.1 Rising government initiatives to support ophthalmology drugs research and increasing drug approvals to support growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Rising focus on clinical research to drive market
  • 11.3.3 UK
    • 11.3.3.1 Ongoing advancements in technology to drive market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing investments and government support to drive market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Growing investments and research to support market
  • 11.3.6 SPAIN
    • 11.3.6.1 Growing geriatric population to drive market growth
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 CHINA
    • 11.4.2.1 Large diabetic population to boost market
  • 11.4.3 JAPAN
    • 11.4.3.1 Growing aging population to intensify demand for effective treatments
  • 11.4.4 INDIA
    • 11.4.4.1 Increasing diabetic cases, government support, and growing availability of biosimilars to support market
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Strong biopharmaceutical sector to drive market growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Strong R&D pipeline and increasing focus on research to support growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Significant rates of visual impairment in region to drive demand for advanced treatments
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing research initiatives and innovations to support market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Growing research initiatives and improving healthcare infrastructure to support growth
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 GROWING FOCUS ON HEALTHCARE TO DRIVE MARKET GROWTH
  • 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET
• 12.3 REVENUE ANALYSIS, 2022-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Molecule footprint
    • 12.5.5.4 Modality footprint
    • 12.5.5.5 Indication footprint
• 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SMEs
    • 12.6.5.2 Competitive benchmarking of startups/SMEs
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 VALUATION OF KEY PLAYERS
  • 12.7.2 FINANCIAL METRICS OF KEY PLAYERS
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 REGENERON PHARMACEUTICALS INC.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product approvals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses & competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches & approvals
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses & competitive threats
  • 13.1.3 BAYER AG
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product approvals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses & competitive threats
  • 13.1.4 NOVARTIS AG
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product approvals
      • 13.1.4.3.2 Deals
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses & competitive threats
  • 13.1.5 ABBVIE
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
  • 13.1.6 APELLIS PHARMACEUTICALS
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product approvals
      • 13.1.6.3.2 Deals
  • 13.1.7 BIOGEN
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product launches & approvals
  • 13.1.8 BAUSCH + LOMB
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product launches & approvals
  • 13.1.9 ASTELLAS PHARMA INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product approvals
      • 13.1.9.3.2 Deals
  • 13.1.10 FORMYCON AG
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product launches & approvals
      • 13.1.10.3.2 Deals
  • 13.1.11 BIOCON
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product approvals
      • 13.1.11.3.2 Deals
  • 13.1.12 SANDOZ GROUP AG
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product approvals
      • 13.1.12.3.2 Deals
  • 13.1.13 SANTEN PHARMACEUTICAL CO., LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product launches
  • 13.1.14 INNOVENT
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product approvals
  • 13.1.15 OUTLOOK THERAPEUTICS, INC.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product approvals
      • 13.1.15.3.2 Deals
  • 13.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Product approvals
      • 13.1.16.3.2 Deals
• 13.2 OTHER PLAYERS (PIPELINE COMPANIES)
  • 13.2.1 OCULAR THERAPEUTIX, INC.
  • 13.2.2 OPTHEA LIMITED
  • 13.2.3 KODIAK SCIENCES INC.
  • 13.2.4 EYEPOINT PHARMACEUTICALS, INC.
  • 13.2.5 ALVOTECH
  • 13.2.6 CLEARSIDE BIOMEDICAL
  • 13.2.7 SHANGHAI HENLIUS BIOTECH, INC.
  • 13.2.8 ADVERUM BIOTECHNOLOGIES, INC.
  • 13.2.9 REMEGEN
  • 13.2.10 SPARINGVISION

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS

List of Tables

• TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
• TABLE 2 OPHTHALMOLOGY DRUGS MARKET: RISK ANALYSIS
• TABLE 3 OPHTHALMOLOGY DRUGS MARKET: IMPACT ANALYSIS
• TABLE 4 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024
• TABLE 5 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024
• TABLE 6 OPHTHALMOLOGY DRUGS MARKET: LIST OF RAW MATERIAL SUPPLIERS
• TABLE 7 OPHTHALMOLOGY DRUGS MARKET: LIST OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES
• TABLE 8 OPHTHALMOLOGY DRUGS MARKET: LIST OF END USERS
• TABLE 9 OPHTHALMOLOGY DRUGS MARKET: LIST OF REGULATORY AUTHORITIES
• TABLE 10 OPHTHALMOLOGY DRUGS MARKET: INDICATIVE LIST OF PATENTS, 2024
• TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 14 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 15 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 16 OPHTHALMOLOGY DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 17 OPHTHALMOLOGY DRUGS MARKET: LIST OF CONFERENCES & EVENTS
• TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
• TABLE 19 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS, BY END USER
• TABLE 20 OPHTHALMOLOGY DRUGS IN CLINICAL PIPELINE, PHASE III (AS OF APRIL 2025)
• TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 22 EXPORTS AND IMPORTS, BY REGION
• TABLE 23 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 24 OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 25 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 26 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 27 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 28 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 29 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023-2030 (USD MILLION)
• TABLE 30 OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023-2030 (USD MILLION)
• TABLE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 33 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 34 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 35 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023-2030 (USD MILLION)
• TABLE 36 OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023-2030 (USD MILLION)
• TABLE 37 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 38 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 39 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 40 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 41 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023-2030 (USD MILLION)
• TABLE 42 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 43 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 44 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 45 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 46 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 47 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 48 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 49 OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 50 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 51 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 52 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 53 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 54 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 55 OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 56 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 57 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 58 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 59 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 60 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 61 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 62 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 63 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 64 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 65 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 66 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 67 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 68 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 69 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 70 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 71 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 72 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 73 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 74 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 75 OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 76 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 77 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 78 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 79 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 80 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 81 OPHTHALMOLOGY DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 82 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 83 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 84 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 85 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 86 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 87 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 88 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 89 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 90 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 91 OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 92 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 93 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 94 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 95 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 96 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 97 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 98 OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 99 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 100 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 101 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 102 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 103 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 104 OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 105 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 106 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 107 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 108 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 109 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 110 OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 111 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 112 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 113 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 114 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 115 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 116 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 117 OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 118 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 119 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 120 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 121 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 122 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 123 OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 124 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 125 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 126 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 127 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 128 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 129 OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 130 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 131 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 132 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 133 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 134 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 135 OPHTHALMOLOGY DRUGS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 136 NORTH AMERICA: MACROECONOMIC INDICATORS
• TABLE 137 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 138 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 139 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 140 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 141 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 142 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 143 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 144 US: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 145 US: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 146 US: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 147 US: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 148 US: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 149 US: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 150 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 151 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 152 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 153 CANADA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 154 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 155 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 156 EUROPE: MACROECONOMIC INDICATORS
• TABLE 157 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 158 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 159 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 160 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 161 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 162 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 163 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 164 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 165 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 166 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 167 GERMANY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 168 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 169 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 170 UK: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 171 UK: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 172 UK: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 173 UK: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 174 UK: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 175 UK: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 176 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 177 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 178 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 179 FRANCE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 180 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 181 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 182 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 183 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 184 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 185 ITALY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 186 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 187 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 188 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 189 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 190 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 191 SPAIN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 192 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 193 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 194 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 195 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 196 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 197 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 198 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 199 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 200 ASIA PACIFIC: MACROECONOMIC INDICATORS
• TABLE 201 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 202 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 203 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 204 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 205 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 206 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 207 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 208 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 209 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 210 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 211 CHINA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 212 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 213 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 214 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 215 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 216 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 217 JAPAN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 218 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 219 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 220 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 221 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 222 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 223 INDIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 224 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 225 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 226 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 227 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 228 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 229 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 230 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 231 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 232 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 233 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 234 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 235 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 236 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 237 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 238 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 239 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 240 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 241 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 242 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 243 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 244 LATIN AMERICA: MACROECONOMIC INDICATORS
• TABLE 245 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 246 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 247 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 248 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 249 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 250 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 251 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 252 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 253 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 254 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 255 BRAZIL: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 256 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 257 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 258 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 259 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 260 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 261 MEXICO: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 262 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 263 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 264 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 265 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 266 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 267 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 268 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 269 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 270 MIDDLE EAST: MACROECONOMIC INDICATORS
• TABLE 271 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 272 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 273 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 274 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 275 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 276 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 277 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 278 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 279 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 280 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 281 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 282 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 283 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 284 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 285 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 286 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 287 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 288 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 289 AFRICA: MACROECONOMIC INDICATORS
• TABLE 290 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023-2030 (USD MILLION)
• TABLE 291 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023-2030 (USD MILLION)
• TABLE 292 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023-2030 (USD MILLION)
• TABLE 293 AFRICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 294 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
• TABLE 295 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 296 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET
• TABLE 297 OPHTHALMOLOGY DRUGS MARKET: DEGREE OF COMPETITION
• TABLE 298 OPHTHALMOLOGY DRUGS MARKET: REGION FOOTPRINT
• TABLE 299 OPHTHALMOLOGY DRUGS MARKET: MOLECULE FOOTPRINT
• TABLE 300 OPHTHALMOLOGY DRUGS MARKET: MODALITY FOOTPRINT
• TABLE 301 OPHTHALMOLOGY DRUGS MARKET: INDICATION FOOTPRINT
• TABLE 302 OPHTHALMOLOGY DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 303 OPHTHALMOLOGY DRUGS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS
• TABLE 304 OPHTHALMOLOGY DRUGS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-MAY 2025
• TABLE 305 OPHTHALMOLOGY DRUGS MARKET: DEALS, JANUARY 2022-MAY 2025
• TABLE 306 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW
• TABLE 307 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED
• TABLE 308 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
• TABLE 309 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 310 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
• TABLE 311 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
• TABLE 312 BAYER AG: COMPANY OVERVIEW
• TABLE 313 BAYER AG: PRODUCTS OFFERED
• TABLE 314 BAYER AG: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
• TABLE 315 NOVARTIS AG: COMPANY OVERVIEW
• TABLE 316 NOVARTIS AG: PRODUCTS OFFERED
• TABLE 317 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
• TABLE 318 NOVARTIS AG: DEALS, JANUARY 2021-MAY 2025
• TABLE 319 ABBVIE: COMPANY OVERVIEW
• TABLE 320 ABBVIE: PRODUCTS OFFERED
• TABLE 321 APELLIS PHARMACEUTICALS: COMPANY OVERVIEW
• TABLE 322 APELLIS PHARMACEUTICALS: PRODUCTS OFFERED
• TABLE 323 APELLIS PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
• TABLE 324 APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021-MAY 2025
• TABLE 325 BIOGEN: COMPANY OVERVIEW
• TABLE 326 BIOGEN: PRODUCTS OFFERED
• TABLE 327 BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
• TABLE 328 BAUSCH + LOMB: COMPANY OVERVIEW
• TABLE 329 BAUSCH + LOMB: PRODUCTS OFFERED
• TABLE 330 BAUSCH + LOMB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
• TABLE 331 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
• TABLE 332 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
• TABLE 333 ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
• TABLE 334 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021-JULY 2024
• TABLE 335 FORMYCON AG: COMPANY OVERVIEW
• TABLE 336 FORMYCON AG: PRODUCTS OFFERED
• TABLE 337 FORMYCON AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MAY 2025
• TABLE 338 FORMYCON AG: DEALS, JANUARY 2021-MAY 2025
• TABLE 339 BIOCON: COMPANY OVERVIEW
• TABLE 340 BIOCON: PRODUCTS OFFERED
• TABLE 341 BIOCON: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
• TABLE 342 BIOCON: DEALS, JANUARY 2021-MAY 2025
• TABLE 343 SANDOZ GROUP AG: COMPANY OVERVIEW
• TABLE 344 SANDOZ GROUP AG: PRODUCTS OFFERED
• TABLE 345 SANDOZ GROUP AG: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
• TABLE 346 SANDOZ GROUP AG: DEALS, JANUARY 2021-JULY 2024
• TABLE 347 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW
• TABLE 348 SANTEN PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED
• TABLE 349 SANTEN PHARMACEUTICAL CO., LTD: PRODUCT LAUNCHES, JANUARY 2021-MAY 2025
• TABLE 350 INNOVENT: COMPANY OVERVIEW
• TABLE 351 INNOVENT: PRODUCTS OFFERED
• TABLE 352 INNOVENT: PRODUCT APPROVALS, JANUARY 2021-MAY 2025
• TABLE 353 OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW
• TABLE 354 OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED
• TABLE 355 OUTLOOK THERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2022-MAY 2025
• TABLE 356 OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2022-MAY 2025
• TABLE 357 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
• TABLE 358 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
• TABLE 359 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS, JANUARY 2022-MAY 2025
• TABLE 360 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022-MAY 2025
• TABLE 361 OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW
• TABLE 362 OPTHEA LIMITED: COMPANY OVERVIEW
• TABLE 363 KODIAK SCIENCES INC.: COMPANY OVERVIEW
• TABLE 364 EYEPOINT PHARMACEUTICALS, INC.: COMPANY OVERVIEW
• TABLE 365 ALVOTECH: COMPANY OVERVIEW
• TABLE 366 CLEARSIDE BIOMEDICAL: COMPANY OVERVIEW
• TABLE 367 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW
• TABLE 368 ADVERUM BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 369 REMEGEN: COMPANY OVERVIEW
• TABLE 370 SPARINGVISION: COMPANY OVERVIEW

List of Figures

• FIGURE 1 OPHTHALMOLOGY DRUGS MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 OPHTHALMOLOGY DRUGS MARKET: RESEARCH DESIGN
• FIGURE 3 OPHTHALMOLOGY DRUGS MARKET: KEY DATA FROM SECONDARY SOURCES
• FIGURE 4 OPHTHALMOLOGY DRUGS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
• FIGURE 5 OPHTHALMOLOGY DRUGS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
• FIGURE 6 PRODUCT REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)
• FIGURE 7 REVENUE SHARE ANALYSIS OF REGENERON PHARMACEUTICALS, INC. (2024)
• FIGURE 8 OPHTHALMOLOGY DRUGS MARKET SIZE VALIDATION FROM PRIMARY SOURCES
• FIGURE 9 OPHTHALMOLOGY DRUGS MARKET: BOTTOM-UP APPROACH
• FIGURE 10 OPHTHALMOLOGY DRUGS MARKET: CAGR PROJECTIONS
• FIGURE 11 OPHTHALMOLOGY DRUGS MARKET: DATA TRIANGULATION
• FIGURE 12 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION)
• FIGURE 13 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION)
• FIGURE 14 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2025 VS. 2030 (USD MILLION)
• FIGURE 16 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• FIGURE 17 GEOGRAPHIC ANALYSIS: OPHTHALMOLOGY DRUGS MARKET
• FIGURE 18 GROWING PREVALENCE OF RETINAL DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH
• FIGURE 19 AFLIBERCEPT ACCOUNTED FOR LARGEST SHARE OF OPHTHALMOLOGY DRUGS MARKET IN NORTH AMERICA IN 2024
• FIGURE 20 HOSPITALS TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 21 NORTH AMERICA LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL OPHTHALMOLOGY DRUGS MARKET DURING FORECAST PERIOD
• FIGURE 22 OPHTHALMOLOGY DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 24 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
• FIGURE 25 OPHTHALMOLOGY DRUGS MARKET: VALUE CHAIN ANALYSIS
• FIGURE 26 OPHTHALMOLOGY DRUGS MARKET: ECOSYSTEM ANALYSIS
• FIGURE 27 OPHTHALMOLOGY DRUGS MARKET: PATENT PUBLICATION TRENDS, JURISDICTION, AND TOP APPLICANT ANALYSIS (JANUARY 2014-DECEMBER 2024)
• FIGURE 28 OPHTHALMOLOGY DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 29 KEY STAKEHOLDERS IN BUYING PROCESS OF OPHTHALMOLOGY DRUGS, BY MODALITY
• FIGURE 30 KEY BUYING CRITERIA FOR END USERS
• FIGURE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT
• FIGURE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT
• FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2022-2024 (USD MILLION)
• FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
• FIGURE 35 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 36 OPHTHALMOLOGY DRUGS MARKET: COMPANY FOOTPRINT
• FIGURE 37 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 38 EV/EBITDA OF KEY PLAYERS
• FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
• FIGURE 40 OPHTHALMOLOGY DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 41 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)
• FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
• FIGURE 43 BAYER AG: COMPANY SNAPSHOT (2024)
• FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT (2024)
• FIGURE 45 ABBVIE: COMPANY SNAPSHOT (2024)
• FIGURE 46 APELLIS PHARMACEUTICALS: COMPANY SNAPSHOT (2024)
• FIGURE 47 BIOGEN: COMPANY SNAPSHOT (2024)
• FIGURE 48 BAUSCH + LOMB: COMPANY SNAPSHOT (2024)
• FIGURE 49 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024)
• FIGURE 50 FORMYCON AG: COMPANY SNAPSHOT (2024)
• FIGURE 51 BIOCON: COMPANY SNAPSHOT (2024)
• FIGURE 52 SANDOZ GROUP AG: COMPANY SNAPSHOT (2024)
• FIGURE 53 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT (2024)
• FIGURE 54 INNOVENT: COMPANY SNAPSHOT (2024)
• FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)